Trial Profile

A Randomized Phase III Study - Conventional Androgen Deprivation Therapy With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and Androgen Deprivation Therapy

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 26 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Luteinising hormone inhibitors; Luteinising hormone stimulants; Prednisone
Indications Prostate cancer
Focus Therapeutic Use

10 Jun 2024 Status changed from active, no longer recruiting to discontinued. (Reason the study was stopped: PI is terminating the study due to slow/low accrual)
25 Jul 2023 Status changed from recruiting to active, no longer recruiting.
13 Mar 2020 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Mar 2020 to 31 March 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com